Following Cadrenal Therapeutics?

Get the free weekly contract digest

The latest new contracts, like Cadrenal Therapeutics’s — who’s behind them and what they mean, delivered to your inbox every week. No credit card, unsubscribe anytime.

Weekly Digest

New new contracts, summarized for you

Straight to Inbox

No login, no app to check — it comes to you

Contract Trends

See who's moving and how much in your market

No credit card required Weekly contract digest

Cadrenal Therapeutics Joins Corporate Council of Anticoagulation Forum

Oct 23, 2024•over 1 year ago

Contract Type

partnership

Ponte VedraBiotechnology

Description

Cadrenal Therapeutics has announced its membership in the Corporate Council of the Anticoagulation Forum, the largest professional organization of anticoagulation specialists, committed to advancing the quality and safety of chronic anticoagulation care globally. Through this partnership, Cadrenal Therapeutics aims to collaborate with the AC Forum to identify and address unmet clinical needs, share cutting-edge research, and promote advocacy and educational initiatives for healthcare professionals to improve outcomes for patients on anticoagulants.

Company Information

Company

Cadrenal Therapeutics

Location

822 A1A NORTH

Ponte Vedra, Florida, United States

About

Cadrenal Therapeutics is a late-stage biopharmaceutical company developing tecarfarin, an oral therapeutic designed to be a superior and safer Vitamin K antagonist (VKA) anticoagulant for patients with implanted cardiac devices or rare cardiovascular (CV) conditions. Cadrenal strives to improve outcomes and reduce adverse events for these patients such as strokes, heart attacks, bleeds, and deaths. These patients also lack approved chronic anticoagulation options besides warfarin, well-known for its serious side effects and frequent drug-drug interactions, resulting in complicated treatment management.

Related People

Suggested for you

Choose your plan to reveal verified contacts

Predictive Intelligence

Strategic

ML-powered predictions for Cadrenal Therapeutics's next move

Learn about Strategic plan

Agreement Insights

Based on industry data

Strategic partnership established

Partnership agreements typically involve technology integration and joint go-to-market strategies

Contract momentum indicator

Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months